贝伐珠单抗联合调强放疗对脑胶质细胞瘤术后患者血清肿瘤标志物的影响  

Effects of bevacizumab combined with intensity modulated radiation therapy on serum tumor markers in patients with glioma after operation

作　　者：袁兴 YUAN Xing(Neurosurgery Department,Xi'an International Medical Center Hospital,Xi'an 710100,China)

机构地区：[1]西安国际医学中心医院神经外科,陕西西安710100

出　　处：《临床医学研究与实践》2025年第12期66-69,共4页Clinical Research and Practice

摘　　要：目的探讨贝伐珠单抗联合调强放疗在脑胶质细胞瘤术后患者中的应用效果。方法选取我院2019年6月至2020年10月收治的106例脑胶质细胞瘤患者为研究对象,随机将其分为对照组(53例,术后实施调强放疗)与研究组(53例,术后实施贝伐珠单抗联合调强放疗)。比较两组的治疗效果。结果研究组的临床缓解率、临床控制率明显高于对照组(P<0.05)。治疗后,研究组的血管内皮生长因子(VEGF)、磷脂酰肌醇蛋白聚糖1(GPC-1)及miR-105水平均明显低于对照组(P<0.05)。治疗后,研究组的白细胞介素-2(IL-2)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均明显低于对照组(P<0.05)。研究组的不良反应总发生率明显低于对照组(P<0.05)。研究组治疗后12、24个月的复发率明显低于对照组(P<0.05)。研究组治疗后24、36个月的生存率高于对照组,中位生存时间长于对照组(P<0.05)。结论贝伐珠单抗联合调强放疗可以改善脑胶质细胞瘤术后患者的血清标志物及免疫炎性因子水平,降低不良反应发生率及复发率,提高其近期疗效及生存率。Objective To explore the application effect of bevacizumab combined with intensity modulated radiation therapy in patients with glioma after operation.Methods A total of 106 patients with glioma admitted in our hospital from June 2019 to October 2020 were selected as the research objects and randomly divided into control group(53 cases,intensity modulated radiation therapy after operation)and study group(53 cases,bevacizumab combined with intensity modulated radiation therapy after operation).The therapeutic effects of the two groups were compared.Results The clinical remission rate and clinical control rate of the study group were significantly higher than those of the control group(P<0.05).After treatment,the levels of vascular endothelial growth factor(VEGF),glypican-1(GPC-1)and miR-105 in the study group were significantly lower than those in the control group(P<0.05).After treatment,the levels of interleukin-2(IL-2),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)in the study group were significantly lower than those in the control group(P<0.05).The total incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05).The recurrence rates of the study group at 12 and 24 months after treatment were significantly lower than those of the control group(P<0.05).The survival rates of the study group at 24 and 36 months after treatment were higher than those of the control group,and the median survival time was longer than that of the control group(P<0.05).Conclusion The bevacizumab combined with intensity modulated radiation therapy can improve the levels of serum markers and immune inflammatory factors in patients with glioma after operation,reduce the incidence of adverse reactions and recurrence rate,and improve the short-term efficacy and survival rate.

关 键 词：贝伐珠单抗 调强放疗 脑胶质细胞瘤 

分 类 号：R739.41[医药卫生—肿瘤]